254 related articles for article (PubMed ID: 16859393)
1. Investigational therapies in the treatment of obesity.
Mancini MC; Halpern A
Expert Opin Investig Drugs; 2006 Aug; 15(8):897-915. PubMed ID: 16859393
[TBL] [Abstract][Full Text] [Related]
2. Current and investigational antiobesity agents and obesity therapeutic treatment targets.
Bays HE
Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100
[TBL] [Abstract][Full Text] [Related]
3. The potential use of selective 5-HT2C agonists in treating obesity.
Smith BM; Thomsen WJ; Grottick AJ
Expert Opin Investig Drugs; 2006 Mar; 15(3):257-66. PubMed ID: 16503763
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapeutic strategies for obesity.
Foster-Schubert KE; Cummings DE
Endocr Rev; 2006 Dec; 27(7):779-93. PubMed ID: 17122357
[TBL] [Abstract][Full Text] [Related]
5. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Srivastava G; Apovian C
Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
[TBL] [Abstract][Full Text] [Related]
6. New targets for obesity pharmacotherapy.
Aronne LJ; Thornton-Jones ZD
Clin Pharmacol Ther; 2007 May; 81(5):748-52. PubMed ID: 17438540
[TBL] [Abstract][Full Text] [Related]
7. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Zieba R
Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763
[TBL] [Abstract][Full Text] [Related]
8. Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists.
Jeon MK; Cheon HG
Curr Top Med Chem; 2009; 9(6):504-38. PubMed ID: 19689363
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-obesity drugs.
Proietto J; Fam BC; Ainslie DA; Thorburn AW
Expert Opin Investig Drugs; 2000 Jun; 9(6):1317-26. PubMed ID: 11060745
[TBL] [Abstract][Full Text] [Related]
10. Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice.
Nonogaki K; Nozue K; Oka Y
Endocrinology; 2006 Dec; 147(12):5893-900. PubMed ID: 16973729
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors.
Wierucka-Rybak M; Wolak M; Juszczak M; Drobnik J; Bojanowska E
J Physiol Pharmacol; 2016 Jun; 67(3):457-63. PubMed ID: 27512006
[TBL] [Abstract][Full Text] [Related]
12. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
13. Current Drug Targets in Obesity Pharmacotherapy - A Review.
Bhat SP; Sharma A
Curr Drug Targets; 2017; 18(8):983-993. PubMed ID: 28245771
[TBL] [Abstract][Full Text] [Related]
14. The hypothalamus and obesity.
Harrold JA; Halford JC
Recent Pat CNS Drug Discov; 2006 Nov; 1(3):305-14. PubMed ID: 18221212
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status.
Parker E; Van Heek M; Stamford A
Eur J Pharmacol; 2002 Apr; 440(2-3):173-87. PubMed ID: 12007534
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction.
Schellekens H; De Francesco PN; Kandil D; Theeuwes WF; McCarthy T; van Oeffelen WE; Perelló M; Giblin L; Dinan TG; Cryan JF
ACS Chem Neurosci; 2015 Jul; 6(7):1186-97. PubMed ID: 25727097
[TBL] [Abstract][Full Text] [Related]
17. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
Miller KJ; Wacker DA
Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
[TBL] [Abstract][Full Text] [Related]
18. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
20. Effect of peptides corresponding to extracellular domains of serotonin 1B/1D receptors and melanocortin 3 and 4 receptors on hormonal regulation of adenylate cyclase in rat brain.
Shpakova EA; Derkach KV; Shpakov AO
Bull Exp Biol Med; 2014 Mar; 156(5):658-62. PubMed ID: 24770752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
